Clinical Trials Directory

Trials / Completed

CompletedNCT05214794

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Maruho Co., Ltd. · Industry
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.

Conditions

Interventions

TypeNameDescription
DRUGnemolizumabnemolizumab will be administered subcutaneous injection

Timeline

Start date
2022-04-20
Primary completion
2024-06-04
Completion
2024-07-30
First posted
2022-01-31
Last updated
2026-02-13
Results posted
2026-02-13

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT05214794. Inclusion in this directory is not an endorsement.

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis (NCT05214794) · Clinical Trials Directory